Liminatus Pharma (NASDAQ:LIMN - Get Free Report) was downgraded by equities researchers at
Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.
Liminatus Pharma Price Performance
NASDAQ LIMN opened at $5.93 on Friday. Liminatus Pharma has a 52 week low of $4.40 and a 52 week high of $33.66.
About Liminatus Pharma
(
Get Free Report)
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Liminatus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liminatus Pharma wasn't on the list.
While Liminatus Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.